Hansoh Pharma says Artemis-011 Phase 3 trial of HS-20093 meets primary PFS endpoint in osteosarcoma

• Hansoh Pharma reported its Phase 3 ARTEMIS-011 trial of risvutatug rezetecan (HS-20093) met the primary endpoint in advanced osteosarcoma.
• The study showed a meaningful delay in disease worsening versus chemotherapy, with supportive signals on survival-related outcomes.
• Safety matched earlier studies, with no new issues flagged.
• Full results will be presented at a future international oncology congress.
• Regulatory talks are planned with China’s NMPA drug review center to support a China BLA filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.